Emergent Biosolutions Inc Cash Flow Conversion Efficiency
Emergent Biosolutions Inc cash flow conversion efficiency. Based on the latest financial reports, Emergent Biosolutions Inc (EBS) has a cash flow conversion efficiency ratio of 0.164x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($56.10 Million) by net assets ($341.40 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Emergent Biosolutions Inc (2004–2025)
Cash flow conversion efficiency of Emergent Biosolutions Inc from 2004 to 2025. This chart illustrates how Emergent Biosolutions Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View EBS share price today for real-time trading data and today's change.
Emergent Biosolutions Inc Cash Flow Conversion Ratio Explained
Emergent Biosolutions Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Emergent Biosolutions Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Emergent Biosolutions Inc ranked by their cash flow conversion efficiency. Also see Emergent Biosolutions Inc (EBS) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vestland Berhad
KLSE:0273
|
-0.018x |
|
Instabank ASA
OL:INSTA
|
N/A |
|
Grupa Azoty Zaklady Azotowe Pulawy SA
WAR:ZAP
|
0.283x |
|
Empire Energy Group Ltd
AU:EEG
|
0.012x |
|
Dabaco
VN:DBC
|
0.008x |
|
Shanghai Dragonnet Tech
SHE:300245
|
-0.035x |
|
Fourlis Holdings S.A.
AT:FOYRK
|
0.155x |
|
Stellar V Capital Corp. Unit
NASDAQ:SVCCU
|
0.000x |
Annual Cash Flow Conversion Efficiency for Emergent Biosolutions Inc (2004–2025)
The table below shows the annual cash flow conversion efficiency of Emergent Biosolutions Inc from 2004 to 2025. Review Emergent Biosolutions Inc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $522.60 Million | $170.60 Million | 0.326x | +168.50% |
| 2024-12-31 | $482.80 Million | $58.70 Million | 0.122x | +138.27% |
| 2023-12-31 | $649.30 Million | $-206.30 Million | -0.318x | -1192.99% |
| 2022-12-31 | $1.39 Billion | $-34.10 Million | -0.025x | -112.33% |
| 2021-12-31 | $1.61 Billion | $321.10 Million | 0.199x | -46.30% |
| 2020-12-31 | $1.45 Billion | $536.90 Million | 0.371x | +114.83% |
| 2019-12-31 | $1.09 Billion | $188.00 Million | 0.173x | +317.70% |
| 2018-12-31 | $1.01 Billion | $41.80 Million | 0.041x | -81.88% |
| 2017-12-31 | $912.35 Million | $208.14 Million | 0.228x | +154.30% |
| 2016-12-31 | $596.21 Million | $53.49 Million | 0.090x | +33.18% |
| 2015-12-31 | $660.02 Million | $44.46 Million | 0.067x | -66.82% |
| 2014-12-31 | $553.20 Million | $112.32 Million | 0.203x | +2.42% |
| 2013-12-31 | $489.17 Million | $96.97 Million | 0.198x | +121.08% |
| 2012-12-31 | $442.13 Million | $39.64 Million | 0.090x | +156.05% |
| 2011-12-31 | $416.73 Million | $14.59 Million | 0.035x | -86.86% |
| 2010-12-31 | $373.56 Million | $99.54 Million | 0.266x | +112.94% |
| 2009-12-31 | $243.81 Million | $30.51 Million | 0.125x | +240.94% |
| 2008-12-31 | $199.35 Million | $7.32 Million | 0.037x | -88.67% |
| 2007-12-31 | $171.16 Million | $55.45 Million | 0.324x | +1204.61% |
| 2006-12-31 | $138.47 Million | $-4.06 Million | -0.029x | -104.15% |
| 2005-12-31 | $59.74 Million | $42.25 Million | 0.707x | +76.50% |
| 2004-12-31 | $22.95 Million | $9.20 Million | 0.401x | -- |
About Emergent Biosolutions Inc
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intrav… Read more